bisphosphonates Update by FDA

Posted by bone9lady @bone9lady, 2 days ago

I have been on and off Fosamax for several years. As of Feb. 2026, the FDA has updated the safety labels for bisphosphonate medications to include a warning that atypical fractures can occur in bones other than the femur. These include the ulna (arm) and tibia (lower leg). The updated warning includes fosamax, reclast, actenol, Boniva. The warning is for those on bisphosphonates longer than 5 years. I just happen to come upon the update or I wouldn't have been aware of it. I'll be discussing it with my endocrinologist. There is no need to panic but knowledge is everything!

Interested in more discussions like this? Go to the Osteoporosis & Bone Health Support Group.

beachesanddreams | @beachesanddreams | 2 days ago

Doctors won’t tell us this, so I thank you for this.

maryandnana | @maryandnans | 2 days ago

Can you send the link so I can read it and so my Dr.

bone9lady | @bone9lady | 1 day ago

I originally saw the info in chat gpt when I was looking for something else. I did a little research and there is a delay of several weeks for FDA updated PDF being loaded to the access data repository. I'm sure your doctor would have better acess than either of us. So it will be a while before we see it in the info included with our fosamax prescription. Sorry I couldn't be of more help.

bone9lady | @bone9lady | 1 day ago

The information to include the ulna and tibia was brought to the attention of the FDA by the American Soxiety for Bone and Mineral Research Society.

dmr4ever | @dmr4ever | 1 day ago

Thanks for this. I worked on drug inserts for an international medical publisher and would normally in the course of my work see these updates. Now that I don’t have that access I don’t know what changes occur. Where did you find this update? I am always concerned about doctors who don’t stay updated for their patients.